Does Emgality Cause Skin Rash at the Injection Site?
Yes, Emgality (galcanezumab) can cause skin rash or redness at the injection site. Common local reactions include pain, redness, itching, swelling, or rash, affecting about 18% of patients in clinical trials—higher than the 13% seen with placebo.[1][2]
How Common Are Injection Site Reactions?
In the pivotal trials (e.g., EVOLVE-1, EVOLVE-2, and REGAIN), injection site reactions occurred in:
- 18% of Emgality users vs. 13% placebo.
- Most were mild to moderate and resolved without stopping treatment.
- Reactions typically appear within hours to days after subcutaneous injection in the abdomen, thigh, or upper arm.[1][3]
What Do Patients Report About Rashes?
Real-world reports on forums and FDA adverse event data describe:
- Red, itchy welts or hives at the site, sometimes lasting 1-3 days.
- Rare cases of severe allergic dermatitis or urticaria requiring antihistamines.
- Fewer than 1% discontinued due to skin reactions.[2][4]
How to Manage or Prevent Injection Site Rash
- Rotate sites between injections.
- Use room-temperature medication and clean skin with alcohol.
- Apply ice or hydrocortisone cream post-injection if rash develops.
- Consult a doctor if rash spreads, blisters, or persists beyond a week—could signal hypersensitivity.[1][3]
Are There Serious Skin Risks Beyond the Injection Site?
Hypersensitivity reactions like rash, hives, or swelling elsewhere occur in <1% but can be serious. No increased risk of systemic skin conditions like psoriasis flares in trials.[1][2]
Who Is More Likely to Get Reactions?
Higher rates in first injections or those with sensitive skin/migraine comorbidities. No clear link to age, sex, or dose (120mg monthly or 300mg loading).[3]
[1]: Emgality Prescribing Information (Lilly)
[2]: FDA Label for Emgality
[3]: Clinical Trial Data (NEJM, Lancet)
[4]: FDA FAERS Database Summary